Ivermectina Giuliani (Ivermectin)

Ivermectina Giuliani is an antiparasitic drug that acts on a variety of helminth and ectoparasite infections.

• Onchocerciasis (river blindness): reduces microfilarial load and helps prevent disease progression.
• Strongyloidiasis: eliminates intestinal larvae and prevents dissemination.
• Scabies: eradicates Sarcoptes scabiei mites, relieving skin lesions.
• Pediculosis (lice infestation): kills head and body lice, stopping infestation spread.
• Other intestinal helminth infections: clears a broad spectrum of nematodes, improving gastrointestinal health.

• Ivermectin binds selectively to glutamate‑gated chloride channels in the nerve and muscle cells of invertebrates. This binding increases chloride ion influx, causing hyperpolarization of the cell membrane, leading to paralysis and eventual death of the parasite while having minimal effect on mammalian cells.

Ivermectina Giuliani may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Dizziness: mild, transient sensation of light‑headedness.
• Nausea: occasional upset stomach.
• Diarrhea: loose stools that resolve spontaneously.
• Abdominal pain: mild cramping.
• Pruritus: itching at the site of infestation or drug administration.
• Headache: mild to moderate intensity.

Serious or Rare Side Effects

• Severe skin reactions: including rash, Stevens‑Johnson syndrome.
• Hepatic injury: elevated liver enzymes or jaundice.
• Neurologic toxicity: seizures, confusion, or ataxia.
• Hypotension: sudden drop in blood pressure.
• Anaphylaxis: rare systemic allergic response.
• Visual disturbances: blurred vision or optic neuritis.

Before prescribing Ivermectina Giuliani, clinicians should consider several safety aspects.

• Assess hypersensitivity: avoid in patients with known allergy to ivermectin or excipients.
• Evaluate liver function: use caution in moderate to severe hepatic impairment.
• Review concomitant CNS drugs: monitor for enhanced neurotoxicity when combined with other central nervous system depressants.
• Pregnancy and lactation: safety data are limited; weigh potential benefits against risks.
• Pediatric use: dosing must be determined by a qualified prescriber based on weight.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Ivermectina Giuliani can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivermectin plasma levels.
• P‑glycoprotein inhibitors (e.g., verapamil): can raise systemic exposure.
• Co‑administration with other antiparasitics: risk of additive neurotoxicity.

Moderate Interactions (Monitor Closely)

• CNS depressants (e.g., benzodiazepines, alcohol): may enhance sedation.
• Anticoagulants (e.g., warfarin): monitor INR for potential changes.
• Diethylcarbamazine: may increase risk of neurologic side effects.
• Antifungal azoles (moderate inhibitors): observe for increased ivermectin exposure.